Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand Some industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were worth it. FiercePharma ...

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Emily Wasserman Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market. ...

Are specialty pharma CEOs worth their salt?

Carly Helfand Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs? FiercePharma ...

Celebrity pitch-folks may not be worth the money, study finds

Tracy Staton Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods? FiercePharma ...

Pharmacist’s theft of $5.6M worth of oxycodone is sure to escalate backlash

Eric Palmer Already dealing with a growing backlash from politicians and law enforcement accusing it of recklessly marketing opioids, the pharmaceutical industry now has to face ...

Wall Street wonders what Shire is worth

Stacy Lawrence The share prices of AbbVie and takeover target Shire keep drifting downward amid sustained uncertainty over a deal. A couple of healthcare investors we talked to feel ...

Glaxo seeks buyers for older products worth up to $12.6B

Carly Helfand GlaxoSmithKline has already made some moves to sell off some of its older meds. But now, it's making more that could end up much, much bigger. FiercePharma News

Novartis’ ‘breakthrough’ muscle drug is worth $4B, if you ask MorphoSys

Damian Garde Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $ ...

Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Tracy Staton Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? FiercePharma News

Sanofi chief: Emerging markets are worth the hassle

Tracy Staton On the path into emerging markets, drugmakers have stumbled across a thorny regulatory bush here, a pricing sinkhole there–not to mention a couple of big bad wolves ...

U.K. gatekeepers unsure Sanofi’s MS drug Aubagio worth the price

Tracy Staton The U.K.'s cost-effectiveness analysts aren't sure Sanofi's new multiple sclerosis pill is worth the price–even at a discount. In a new review, the National ...

GlaxoSmithKline to supply U.S. with $196M worth of anthrax fighter

Tracy Staton GlaxoSmithKline inked a $ 196 million contract to supply its anthrax remedy, raxibacumab, to the U.S. government FiercePharma News
Page 1 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS